Dr. Sébastien Fortin PhD is a regular researcher at the Centre de recherche du CHU de Québec-Laval University, Director of a pharmaceutical chemistry laboratory located at the Hôpital Saint-François d’Assise, and Associate Professor at Laval University’s School of Pharmacy. He is author and co-author of 28 publications and co-inventor of 3 patents on the technologies that he develops. Dr. Fortin is the recipient of several awards and honors, including the Jean-François St-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research (CIHR) and the 2011 award for the best doctorate in cotutelle awarded by the Ministère des Relations internationales and the Consulat général de France à Québec. His research focuses on the design and development of new anticancer agents for use in personalized medicine.

Development of new drugs for personalized cancer chemotherapy

In Canada, cancer is the leading cause of death, followed only by cardiovascular diseases. Cancer is therefore a major public health problem. Despite recent medical breakthroughs, the ability to cure all cancer patients remains elusive. Consequently, we need to develop new treatments that will be more efficient, and more selective against cancer tumors, with the aim of improving the life expectancy and the quality of life of cancer patients. The aim of my research program is to design and prepare new anticancer agents exhibiting optimal biopharmaceutical and anticancer properties suitable for preclinical and clinical studies. My research themes are divided in two parts: 1) development of new inhibitors of DNA repair and replication mechanisms and 2) development of new inhibitors targeting cells deficient in homologous recombination. My research programs involve and focus on several interrelated and complementary disciplines, including molecular design and modeling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to the development of new, efficient and personalized anticancer treatments.

Hôpital Saint-François d'Assise
10, rue de l'Espinay
D0-705C
Québec, Québec
Canada G1L 3L5

Latest news

Data not available

33 entries « 3 of 4 »

Fortin S, Wei L, Moreau E, Lacroix J, Cote MF, Petitclerc E, Kotra LP, C-Gaudreault R

Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.

Journal Article

J Med Chem, 54 (13), pp. 4559-80, 2011, ISSN: 0022-2623.

Abstract | Links:

Trzeciakiewicz A, Fortin S, Moreau E, C-Gaudreault R, Lacroix J, Chambon C, Communal Y, Chezal JM, Miot-Noirault E, Bouchon B, Degoul F

Intramolecular cyclization of N-phenyl N'(2-chloroethyl)ureas leads to active N-phenyl-4,5-dihydrooxazol-2-amines alkylating β-tubulin Glu198 and prohibitin Asp40.

Journal Article

Biochem Pharmacol, 81 (9), pp. 1116-23, 2011, ISSN: 0006-2952.

Abstract | Links:

Fortin S, Bouchon B, Chambon C, Lacroix J, Moreau E, Chezal JM, Degoul F, C-Gaudreault R

Characterization of the covalent binding of N-phenyl-N'-(2-chloroethyl)ureas to {beta}-tubulin: importance of Glu198 in microtubule stability.

Journal Article

J Pharmacol Exp Ther, 336 (2), pp. 460-7, 2011, ISSN: 0022-3565.

Abstract | Links:

Fortin S, Moreau E, Lacroix J, Cote MF, Petitclerc E, C-Gaudreault R

Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N'-(2-chloroethyl)ureas.

Journal Article

Eur J Med Chem, 45 (7), pp. 2928-37, 2010, ISSN: 0223-5234.

Abstract | Links:

Fortin S, Lacroix J, Cote MF, Moreau E, Petitclerc E, C-Gaudreault R

Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site.

Journal Article

Biol Proced Online, 12 (1), pp. 113-7, 2010.

Abstract | Links:

Bawolak MT, Fortin S, Bouthillier J, Adam A, Gera L, C-Gaudreault R, Marceau F

Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors.

Journal Article

Br J Pharmacol, 158 (5), pp. 1375-86, 2009, ISSN: 0007-1188.

Abstract | Links:

Fortin S, Wei L, Moreau E, Labrie P, Petitclerc E, Kotra LP, C-Gaudreault R

Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin.

Journal Article

Bioorg Med Chem, 17 (10), pp. 3690-7, 2009, ISSN: 0968-0896.

Abstract | Links:

Fortin S, Labrie P, Moreau E, Wei L, Kotra LP, C-Gaudreault R

A comparative molecular field and comparative molecular similarity indices analyses (CoMFA and CoMSIA) of N-phenyl-N'-(2-chloroethyl)ureas targeting the colchicine-binding site as anticancer agents.

Journal Article

Bioorg Med Chem, 16 (4), pp. 1914-26, 2008, ISSN: 0968-0896.

Abstract | Links:

Moreau E, Fortin S, Lacroix J, Patenaude A, Rousseau JL, C-Gaudreault R

N-Phenyl-N'-(2-chloroethyl)ureas (CEUs) as potential antineoplastic agents. Part 3: role of carbonyl groups in the covalent binding to the colchicine-binding site.

Journal Article

Bioorg Med Chem, 16 (3), pp. 1206-17, 2008, ISSN: 0968-0896.

Abstract | Links:

Fortin S, Moreau E, Lacroix J, Teulade JC, Patenaude A, C-Gaudreault R

N-Phenyl-N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety?

Journal Article

Bioorg Med Chem Lett, 17 (7), pp. 2000-4, 2007, ISSN: 0960-894X.

Abstract | Links:

33 entries « 3 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Appui financier du Fonds de recherche de l’Hôpital Saint-François d'Assise pour le support de doctorants.es au laboratoire du Dr Sébastien Fortin, Subvention, Fondation de l'Université Laval, from 2020-05-01 to 2022-04-30
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2016-04-01 to 2021-03-31
  • Conception de nouveaux agents anticancéreux ciblant les mécanismes de réparation et de réplication de l'ADN en vue de leur utilisation en médecine personnalisée, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2018-07-01 to 2022-06-30
  • Conception de nouveaux agents anticancéreux ciblant les mécanismes, Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2018-07-01 to 2022-06-30
  • Les phénylureidobenzènesulfonates, une nouvelle thérapie de différenciation pour le traitement de la leucémie myéloïde aiguë : preuve de concept, Subvention, Fondation de l'Université Laval, from 2020-02-01 to 2022-01-31

Recently finished projects

  • Soutien à la recherche du Fonds de recherche de l'Hôpital Saint-François d'Assise, Subvention, Fondation de l'Université Laval, from 2016-05-01 to 2020-04-30
Data provided by the Université Laval research projects registery